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Abbreviations: CNS, central nervous system; iPSC, induced 
pluripotent stem cells; HD, huntington’s disease; PD, parkinson’s di-
sease; AD, alzheimer’s disease; ALS, amyotrophic lateral sclerosis; 
MS, multiple sclerosis; TBI, traumatic brain injury; NSC, neural stem 
cells; PDMS, poly(dimethylsiloxane)
Introduction
The use of cells as building materials provides a powerful tool to the 
fields of both regenerative medicine as a broad aspect and in particular 
to tissue engineering, with the potential to deliver a tremendous 
amount of information both in vivo as cell-based therapies and/or in 
vitro as cell models. Combining cells with specialized biomaterials, 
suitable biochemical growth/differentiation factors, extracellular 
matrices (‘scaffolds’) and diverse biomimetic environments creates 
a myriad of opportunities for extensive study of tissues in both 
physiological and pathological forms, and the creation of strategies 
for regenerating damaged tissues.1,2 Due to the complexity of living 
tissue, with multiple cell types acting in synergy to give the whole 
tissue its function, there are many efforts to model tissues in vitro. 
For the most part such modelling aims strikes a balance between the 
ability to create functional tissue structures and the simplification in 
the complexity observed in vivo. Organoids have been highlighted as 
one of the major advances in developing suitable models for various 
specific tissue types. Amongst these are intestine3 lung4–6 and kidney,7,8 
to name a few. Further models of heart, cartilage and skin, as well as 
functional systems such as the vascular, endocrine, musculoskeletal, 
and nervous systems have been reviewed by Benam et al.9 Body- and 
human-on-a-chip systems further aim to draw connectivity between 
each of these separate models in order to mimic basic physiological 
function on a larger scale.10,11
Tissue models must present a reasonable mimic of normal 
physiological function in order that they are deemed useful; it is this 
‘use’ which is now expanding as we gradually increase our micro/
nanofabrication capabilities to guide complex tissue engineering 
approaches, better replicating normal and diseased function. Our 
models allow for better understanding of function and dysfunction, 
disease spread and how efforts for treatment may be optimised. Pre 
clinical assessment of disease is certainly one of the tissue engineering 
‘holy grails’ with personalised medicine approaches being a major 
future ambition for research within this area. In this review we cover 
those developed for the central nervous system (CNS), namely neural 
tissue engineering, which remain one of the most challenging tissue 
engineering areas due to the complexity of interconnectivity and 
communication between the plethora of cell types, all requiring very 
specific architecture on the cell-level to infer function. In this review 
we include the range of approaches used for both normal and diseased 
CNS models. 
The engineering challenge 
Neural tissue engineering reaches a new level of complexity due to 
the fact that unlike other tissues, the structure and distinct architecture 
is seen even at the cellular level and is vital to assure functionality. 
The human brain contains many combinations of intricate micro- and 
macroscopic12 connections- whether morphological, functional, or 
both-occurring at specific spatial nodes at specific temporal intervals, 
creating an extremely complex network between vast cell populations, 
making the brain extremely challenging to model in vitro. An average 
adult human brain will have a mass of 1.5 kg containing100 billion 
neuronal cells (neurons, which transmit and receive information 
through electrical signals, forming synapses with other neurons) and 1 
trillion non-neuronal cells (glia, structural cells of the brain, composed 
mainly of astrocytes, oligodendrocytes and microglia).13 In addition, 
each neuron can connect with other neurons (and astrocytes14) via 
synapses, at an average of 7000 connections per neuron, resulting in 
approx. 100 trillion connections in the adult human brain.15,16
Due to this complexity, it has been difficult to develop living 
artificial neural networks that are reproducible, can be scaled-up and 
are low-cost, reliable, as well as efficient, robust, and reproducible,1,2 
both during standard physiological situations and abnormal 
pathological situations during disease.17,18 Some of the many design 
considerations for neural models are highlighted in Table 1. 
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Abstract
The increased prevalence of neurological diseases across the world has stimulated a 
great deal of research into the physiological and pathological brain, both at clinical 
and pre-clinical level. This has led to the development of many sophisticated tissue 
engineered neural models, presenting greater cellular complexity to better mimic 
the central nervous system niche environment. These have been developed with the 
ambition to improve pre-clinical assessment of pharma and cellular therapies, as well 
as better understand this tissue type and its function/dysfunction. This review covers 
the necessary considerations in in vitro model design, along with recent advances in 
2Dculture systems, to 3D organoids and bio-artificial organs.
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Table 1 What to consider when planning an in vitro neural model, adapted from19
Design consideration Culture options
Brain area to model
(cell type to use)
Most common areas reported in literature are cortex, hippocampus, cerebellum, spinal cord and sensory 
ganglia.
Cell culture class
Primary cells and secondary cell lines. Primary cells are isolated directly from tissues and therefore best 
represent the endogenous phenotype, but are difficult to maintain; there are also ethical considerations for 
primary cells and further difficulties when human cells are required. Immortalized cell lines can be maintained 
indefinitely, but may have excessive variation from the original in vivo genotype/phenotype.
Cell developmental age
As the brain develops cell types mature into the various populations that may be required. Maturation of the 
brain structure sees compartmentalisation, after which time it may be difficult to extract the neuronal cells 
due to their delicate nature and intrinsic engulfment by the body of supporting cells. A compromise between 
dissection from younger tissue means that cells can be harvested in higher purity, be easier to culture, but 
with the caveat that that they might not be functionally mature.
Similarities to the human nervous 
system
Can use adult human iPS cells, embryonic/foetal human cells, animal cell lines or primary animal cells to 
increase similarity to in vivo CNS.
Culture type Can culture tissue/organ slices or dissected disperse individual cell populations.
Preservation of in vivo organisation
(2D versus 3D)
Neural cells can grow effectively in a 2D planar culture (monolayer) or 3D matrix (neurosphere), with 2D 
being the most inaccurate compared to anatomy in vivo. An important consideration from the perspective of 
cell-cell and cell-matrix interactions, which are numerous in 3D but limited in 2D. Can disaggregate or re-
aggregate cells.
Electrophysiological integrity
Are the cells functional within the model? The neural cells within the model should have similar electrical 
activity as the same cell type in vivo.
Culture environment Extracellular fluid composition, temperature, pH, gas phase, substrate, dimensions.
Model material Non-toxic, non-inflammatory, non-allergenic, non-carcinogenic, light, soft, mechanically durable and chemically 
stable
Neural diseases
There are multiple ways to categorise neurological diseases, but the 
major types include those caused by: genetic disorders (Huntington’s 
disease (HD)20 and muscular dystrophy21); cellular degeneration 
(Parkinson’s disease (PD)22 and Alzheimer’s disease (AD)23); 
movement disorders (neuromuscular disease such as amyotrophic 
lateral sclerosis (ALS)24 and multiple sclerosis (MS)25); damage to 
central nervous system blood supply (stroke26); electrophysiological 
disorders (epilepsy27); physical injury (spinal cord injury (SCI),28 
traumatic brain injury (TBI)29); cancer (such as glial and non-glial 
tumours30) and infection (bacterial meningitis31). 
The drivers for the development of tissue engineered models 
of disease revolve around our current inability to understand (dys) 
function of the CNS and further how to better treat neurodegenerative 
disorders that are becoming increasing prevalent. Large pharmaceutical 
companies have spent billions of dollars over the past decade trying 
to address these issues, but have now stepped back from major 
funding efforts due to lack of progression. With increasing demand 
to new therapies, both pharmaceutical and cellular therapies, and 
our increasing capabilities to better fabricate tissues with a degree of 
complexity, tissue engineered models are providing a stepping stone 
for the research of new ways to move this research area forward. Key 
features of the diseases and disorders being of high interest by this 
growing sub-field of regenerative medicine are highlighted in Table 2. 
 Table 2 Comparison of the key components of the major neurological disorders
Stroke 
(traumatic) Epilepsy
Parkinson’s 
disease
Huntington’s 
disease
Alzheimer’s 
disease
Amyotrophic 
lateral sclerosis
Prevalence
Second most 
common form of 
death, 16 million 
first-time strokes 
in 2005, projected 
to 23 million in 
2030.32
Most common 
neurological disorder, 
65 million cases 
worldwide,33 50% of 
cases begin in childhood 
or adolescence.27
>1 per 1000 in 
Europe and 7 million 
cases globally.34,35
5.70 per 100,000 
in Europe, North 
America and 
Australia.20
Approx. 0.4% of 
world pop. (26.6 
million), predicted 
to quadruple 
by 2050. Older 
age groups are 
more likely to be 
diagnosed with 
AD.36,37
2.2 per 100,000 
per year in Europe, 
with peak onset 
at 58-63 years old 
(sporadic) and 
47-52 years old 
(familial, 5-10% of 
cases).38
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Stroke 
(traumatic) Epilepsy
Parkinson’s 
disease
Huntington’s 
disease
Alzheimer’s 
disease
Amyotrophic 
lateral sclerosis
Main 
Symptoms
Unilateral inability 
to move and 
loss of vision, 
muscle weakness. 
Symptoms 
largely depend 
on the brain area 
affected.39
Seizures: from 
momentary loss of 
awareness to extended 
uncontrollable 
movement. ‘Unprovoked’ 
and unpredictable.27,40
Cognitive and 
behavioural 
limitations resulting 
in dementia, along 
with rest tremor, 
bradykinesia and 
rigidity.9,41
Chorea, 
general physical 
instability, 
cognitive 
degeneration, 
behavioural 
changes.46
Progressively 
worsen with 
age, from mild 
cognitive difficulty 
to serious issues 
with language, 
motor function, 
and memory 
(Waldemaret al. 
2007).
Cognitive function 
is largely unaffected 
in most cases,42 
can initially present 
in the limbs 
(wastage/weakness, 
spasticity) or the 
trunk (speech, 
swallowing) with 
eventual spread to 
the limbs.38
Causes
30-40% cases 
idiopathic, of the 
remainder 87% 
are ischemic, 13% 
haemorrhagic.39,43
60% cases idiopathic. 
Other cases result after 
serious brain trauma, a 
minority have a genetic 
component.44
Most cases are 
idiopathic, a minority 
of cases are caused 
by mutations to a 
number of genes.45
Autosomal-
dominant 
disorder caused 
by a mutation in 
the Huntingtin 
gene.46
Mostly idiopathic, 
can be familial with 
49-79% heritability. 
Potentially linked 
to the beta-amyloid 
protein.47,48
5-10% of cases 
inherited, 
potentially due to 
SOD1 mutations.49 
Remainder are 
idiopathic, may be 
caused by brain 
trauma or drug 
use.38
Pathology
Irregular levels 
of blood in the 
brain (ischemic) 
and/or bleeding 
in the brain 
(haemorrhagic) 
result in cell 
death.39
Electrophysiological 
dysfunction in the brain, 
with an excessive surge 
of electrical activity and 
linked to synchronicity, 
potentially causing 
seizures27
Loss of dopaminergic 
neurons in the 
substantia nigra 
results in decreased 
dopamine levels, 
Lewy bodies and 
Lewy neuritis.45
Huntingtingene 
codes for 
huntingtin 
protein in all 
brain regions 
but only affects 
a select few, 
degenerating the 
striatum.50
Degeneration 
of temporal and 
parietal lobes, 
frontal cortex and 
cingulate gyrus, 
alongside changes 
in neurotransmitter 
levels.51
Death of upper 
and lower motor 
neurons in the 
motor cortex, 
brain stem, 
spinal cord.38 
This cell death 
may be due to 
defects in protein 
degradation leading 
to aggregation.52
Table Continued...
The importance of tissue model selection
The vast majority of neurological diseases are not well understood. 
This lack of knowledge concerning causative mechanisms of human 
neurodegenerative disease outlines the vital importance of developing 
efficient pre-clinical research methods, especially when taking into 
account the prevalence and fatality of some of the diseases. More 
effective pre-clinical assessment is needed to address the fundamental 
underlying mechanisms behind develop in neurological disorders, so 
as to further refine how we model diseases in pre-clinical research. 
Current pre-clinical models are unable to accurately predict the 
efficacy of pharmaceuticals or cellular therapies within human disease 
patients. Dr Don Ingber, Director of Harvard University’s Wyss 
Institute of Biologically Inspired Engineering (July/August 2012, 
MIT Tech. Review) has spoken out about this in a topical interview:
“… the drug development model is actually broken. It takes 
many, many years to get a drug to market, it’s incredibly expensive, 
innumerable animal lives are lost – and then the results from animals 
‘usually’ don’t predict what happens in human. So this is a huge cost 
to the economy and to the pharmaceutical industry.”
There is a need for new pre-clinical models to determine at a 
much earlier stage whether the treatment in question is going to be 
effective, thus eliminating unnecessary clinical trials. Current pre-
clinical models can be either in vivo or in vitro. But there is often a 
considerable lack of diseased tissue for study, especially concerning 
human models, due to biopsies involving limited environmental 
control, variable sample thickness, and destruction of countless input/
output connections from both neuronal and glial cells53 upon biopsy. 
Therefore, pre-clinical work usually relies upon animal models, either 
as a whole for in vivo study, or as a source of brain slices or neuronal/
glial cells for in vitro culture.
Animal models are a necessary regulatory hurdle for any medical 
therapy, although there are well known pitfalls resulting from the 
difficulties of measurement or understanding of mode of therapy 
action in the CNS, or indeed difficulty to measure the output of effect; 
these are not least beset by the ethical considerations of using animals 
for research, nor their non-accurate mimics for human assessment. 
Whole animal models are limited by the behavioural outputs, 
alongside the treatment zone of either pharmaceutical or cellular 
therapy delivery encompassing a large volume if not the whole tissue. 
The same is observed even for tissue slices, albeit that these do offer 
a larger sampling size from a single animal and potential to better 
interrogate tissue at the cell level. For in vitro developed models the 
choice of cells and their presentation are the initial key design factors. 
Organoid models do permit in some cases real-time monitoring 
of tissue by microscopy and function by e.g. electrode insertion, 
although the complexity of these cannot realistically achieve anything 
like that observed for normal CNS tissue. Here we give some insight 
into selection considerations made during the development of these 
in vitro systems. 
The most basic in vitro neural models make use of populations 
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of neurons being used after removal or culture of the cells to isolate 
specifically neurons rather than to include glial cells. The absence of 
glia markedly decreases the accuracy of the model as a mimic of the 
in vivo CNS, where astrocytes and other glial cells play a vital role in 
the brains structure and function. As most biopsies and samples from 
brains feature a physiologically-relevant mixture of neuronal and glial 
cells, neuronal-only cell models are often derived from exogenous 
sources such as neural stem cells (NSCs), artificial sources such as 
iPSC cells or cancer cell lines such as the human neuroblastoma cell 
line SH SY5Y, all discussed further below. Despite the progress made 
with neuronal-only in vitro cell models, the absence of glia is a major 
disadvantage of these models, only with a physiologically relevant 
mixture of neuronal and glial cells can we approach a good mimic 
of the highly complex in vivo CNS niche. Such mixed cultures can 
be isolated from in vivo sources such as the Sprague-Dawley rat.54 
The combination of both makes primary neuronal-glial cultures a 
powerful in vitro model for studying neurological disease.
Induced pluripotent stem cells 
Due to their pluripotent nature iPSCs can differentiate down 
a neural pathway and be used to generate neural tissues. By using 
neurologically-affected sources (e.g. obtained from PD patients) 
iPSCs can be used to model diseases, being genetically identical 
to the disease source. Table 3 features a list of recent iPSC 
neurodegenerative disease models: While iPSCs are a versatile tool 
for studying neurological disease, sometimes referred to as a ‘disease-
in-a-dish’ model, they have several limitations. There are only a 
limited number of individual lines used to model disease mechanisms, 
and all of them exhibit significant biological variance, making them 
somewhat unpredictable with decreasing reproducibility between 
experiments.55,56 Such variability results from the reprogramming 
process, culture-induced differences due to the lack of robust 
differentiation protocols, and differences in genetic background 
between patients.57
Table 3 Recent iPSC models of neurodegenerative diseases
Disease type Cell modelled Results Reference
Parkinson’s Dopaminergic neurons
Fibroblasts from five PD patients were reprogrammed and differentiated into 
dopaminergic neurons. 58
Parkinson’s Dopaminergic neurons
Fibroblasts from PD patients differentiated into dopaminergic neuron-like cells, 
showing similar markers, uptake, and electrophysiology to in vivo dopaminergic neurons, 
provided relief in a rat PD model. PD-related biochemical defects from donor cells are 
maintained. Synuclein aggregation can be triggered.
59
Familial alzheimer’s Neurons
Fibroblasts with presenilin 1/2 mutation (a cause of autosomal-dominant early-onset 
AD) reprogrammed to neurons that have increased toxic Aβ42 secretion, similar to AD 
pathology in vivo.
6
Alzheimer’s in down 
syndrome (trisomy 
21)
Cortical neurons
Generated cortical neurons developed AD pathology in months rather than years. Cells 
exhibited insoluble intracellular and extracellular amyloid aggregates as well as hyper-
phosphorylated tau protein in cell bodies and dendrites.
61
Alzheimer’s (familial 
and sporadic) Neurons
Generated neurons showed normal electrophysiology but higher levels of pathological 
markers (phospho-tau, aGSK-3b, Aβ(1-40)) and accumulation of large RAB5-positive 
early endosomes.
62
Alzheimer’s (familial 
and sporadic)
Neurons Generated neurons showed Aβ oligomer accumulation, which lead to oxidative stress. 
Treatment with docosahexaenoic acid alleviated the stress.
63
ALS (familial) Motor neurons Generated motor neurons formed cytosolic aggregates and mutation TDP-43 similar to in vivo ALS. 64
ALS Motor neurons
Generated motor neurons contained SOD1 mutation and exhibited neurofilament 
aggregation and neurite degeneration with absent glia. Expression of neurofilament L 
protein corrected the neurofilament proportions, halting neurite degeneration.
65
ALS Motor neurons
Generated motor neurons expressed markers of unfolded protein and endoplasmic 
reticulum stress, caused by repeats in the C9 or f72 locus suggesting the mutations act 
through common pathways.
66
Neural stem cells 
There is a growing interest in using stem cells for the treatment of 
neurodegenerative diseases, especially multipotent stem cells with a 
neural origin. Several studies have used NSCs as a neuronal-only in 
vitro neural cell model. NSCs were used as a transplant by Ono et al. 
during the development of an in vitro NSC model of schizophrenia, 
using NSCs from E13.5 foetal rats to repair damage to primary cortical 
neural cultures from E18 foetal rats. NMDA receptor antagonist MK-
801 as well as serum/nutrient deprivation stress was used to damage 
the cortical neurons, and exogenous NSCs were transplanted to 
determine any neuroprotective effects. This study found that NSCs 
exerted neuroprotective effects, altered cell survival signalling by 
indirect cell-cell contact, restoration of protein levels (reduced by the 
stress) and had a general anti-apoptotic effect on cells affected by both 
forms of damage, rescuing the damaged cortical neurons.67
Another effect of NSCs on damaged neural cell populations 
is a paracrine effect via the release of exosomes, affecting cell-
cell communication. Bonafede et al.68 developed an in vitro model 
of ALS through motor neuron-like NSC-34 cells (NSCs that over 
express human ALS mutations SOD1 (G93A, G37R or A4V)) that 
exhibited oxidative stress found in ALS in vivo. The NSC-34 cells 
were protected from this stress, increasing cell viability, by treating 
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the cells with exosomes derived from murine adipose-derived stromal 
cells. The study promotes exosomes as a potential therapy in motor 
neuron disease.
NSCs represent a flexible platform through both their ability to 
differentiate into multiple cell types in vitro, but their ability to be 
genetically modified to better match the diseases they are modelling 
(as exampled above with the NSC-34 mutants exhibiting oxidative 
stress similar to that found in ALS). NSCs have been genetically 
modified to stably express and secrete neprilysin (known under 
several names, including neutral endopeptidase or NEP), an enzyme 
that degrades beta-amyloid protein (Aβ), one of the causative 
elements of Alzheimer’s disease. In this study, NEP-expressing NSCs 
were found to significantly reduce Aβ pathology when transplanted, 
in both proximal and distal areas.69 Further use of NSCs (as well as 
embryonic stem cells (ESCs) and iPSCs) as in vitro neural models of 
disease is summarised by.70
SH-SY5Y human neuroblastoma cell line 
Primary cells derived from the CNS are limited in that once they 
differentiate and mature into neurons they reach a static population and 
propagate no further. The advantages of using a cancer cell line such 
as the SH-SY5Y neuroblastoma cell line is that they can be cultured 
indefinitely, and as such the line is often used for in vitro neural models 
of disease, also due to their availability, ease of culture and exhibition 
of dopaminergic markers. This cell line has been especially useful for 
modelling Parkinson’s disease. However, Kovalevich et al.71 identify 
three characteristics of SH SY5Y cells that should be considered for 
in vitro studies. Firstly, SH-SY5Y cultures include adherent (cells 
that grow when attached to surfaces) and floating cells (cells that 
grow unattached), with the floating cells having a unique phenotype 
but mostly discarded during media changes, the focus being on the 
adherents. Secondly, SH-SY5Y cultures produce both neuroblast-
like (N) and epithelial-like (S) subtypes, with only the N morphology 
exhibiting dopaminergic markers and enzymatic activity. However, 
the N-type cells can be specifically selected for by forcing the SH-
SY5Y cells to differentiate to a mature neuron-like phenotype, which 
is the final characteristic, the most common means of differentiation 
being treatment with retinoic acid (RA).71–73
Due to their expression of dopaminergic markers, SH-SY5Y cells 
are used most frequently to model Parkinson’s disease in vitro. A 
recent review of these studies demonstrates several such models,74 
where Parkinson’s disease is simulated in a number of ways. One 
method involves over expressing α-synuclein (or the A53T/A30P 
mutants),75,76 to varying success. A more popular method involves 
mimicking abnormal mitochondrial function and the associated 
oxidative stress and autophagy with the use of specific drugs such as 
MPP+,77,78 6-OHDA79,80 and paraquat;81,82 or through gene knockouts 
such as PINK1 silencing.83
Co-culture models
The interaction between neurons and astrocytes is a vital 
component to include in any in vitro neural model, as demonstrated 
by an ALS model where mutant SOD1 motor neurons were adversely 
affected when cultured with mutant glial cells, with the glia having 
a direct, non-cell autonomous effect on motor neuron survival.84 
Other studies have made use of co-cultures for observation of pharma 
effects on gene regulation. Nissou et al.85 presented work on vitamin 
D deficiencies within neuronal/glia co-cultures, highlighting 17 genes 
related to neurodegenerative diseases, 10 of these encoding proteins 
potentially limiting the progression of Alzheimer’s disease.
Wang et al.86 have presented models co-culturing neuronal-glia 
mixtures in similar ratios as would be observed in vivo: 37% neurons, 
51% astrocytes, 7% microglia and 5% other cells, after 14days culture 
in vitro (DIV).These models use the complex physiological neuron-
neuron, glia-glia and neuron-glia interactions to increase the accuracy 
of the model to the in vivo environment, as well as the fact that they 
can be obtained from various brain regions (cortex, subcortical nuclei, 
hippocampus, etc) to demonstrate regional differences in susceptibility 
during certain neurodegenerative diseases, such as Parkinson’s and 
Huntington’s disease which are mainly localised to the basal ganglia 
region, and generally how neurons and glia from different regions are 
inherently different.87
The presence of astrocytes and microglia in culture give these 
cultures the ability to better model certain diseases, especially diseases 
where inflammation is involved as an important disease modifying 
factor, considering that microglia and astrocytes are involved in 
secretion of inflammatory mediating factors.88 Microglia in particular 
play an important role in injury and recovery, as shown when activated 
microglia mediate damage to injured dopaminergic cells, showing how 
inflammatory reactions could specifically target oxidative injuries.89 As 
well as being cultured together as a mixture, neurons and glia can also 
be co-cultured in a segregated manner, with neurons and glia actively 
signalling each other while not being in contact.90 The activation of 
glia being significant, as this activation has been shown to play a role 
in the pathogenesis of various neurodegenerative diseases.91 However, 
generating segregated cultures demonstrates a contradiction: how can 
different cell cultures be physically separated from each other while 
still being allowed to communicate (otherwise the result is simply 
two isolated cultures), creating a segregated co culture? One effective 
answer is the use of micro-scale features to allow only the processes 
(axons, dendrites, generalised as neurites or processes) from each 
culture to interact, with the cell bodies themselves segregated. To this 
end, process outgrowth must be directed and controlled, often using 
chemical patterns or micro-channels.
Directing neurites
Micro- and nano-scale physical features have a marked effect on 
cell culture; cells experience the features through mechanotransduction 
and undergo biochemical, morphological and genetic alterations.92 
For example, growing human NSCs on micro-scale grooves resulted 
in elongation and bipolar growth, with the cells aligning to the 
grooves and growing along the groove wall.93 Primary cells have also 
been used to develop direction cues as would be observed in vivo, 
using radial glia to guide neurons.94 This ability to align and direct 
cells allows control over the direction of neuron outgrowth, and the 
formation of segregated neuronal-glial ‘circuits’. There is a wealth 
of literature with many reviews on the topics of surface texturing, 
chemical patterning and cell control.95 
The ability to segregate and direct neural cells has evolved over 
the last 40 years or more, starting with the Campenot chamber in 
1977,96,97 which isolated processes of long-projection neurons using 
a Teflon TM barrier and micro-scale grooves. The chamber was 
modified to accommodate all types of neurons, including those with 
shorter processes such as inter-neurons.98 Whilst these models allowed 
the separation of cell body and elongating neurites, they could only 
accommodate one cell type, with no consideration of co culturing 
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cells at this time. Based on these shortcomings, a new model was 
developed: two chambers linked by micro-scale channels, fabricated 
via photo- and soft-lithography and sealed to a surface, resulting in a 
microfluidic device for controlled segregated cell culture.99–101 This 
model has formed the basis for microfluidic cell culture devices, being 
modified to increase in complexity and therefore in effectiveness as an 
in vitro neural model (a particular example features seven chambers 
and glial cell interaction102). All of these models can be seen below in 
Figure 1.
Figure 1 The evolution of compart mentalised neural models. (A) The 
Campenot chamber, a TeflonTM barrier sealed onto a collagen coated dish 
with parallel lines scratched 200µm apart. Neurons are plated in the centre 
area and processes grow and align into the other chambers (B) The Ivins 
chamber, a TeflonTM semi-circle sealed onto a polylysine-lamnin coated dish, 
covered by a cover slip. Neurons are plated outside the TeflonTM ring and 
grow under the cover slip into the main chamber, where they can be studied. 
(C) Two chambers (each chamber consists of two 8 mm diameter wells 
connected by a rectangular section) connected by 120 micro-scale grooves 
(10µm wide, 3µm high and 150µm long, spaced 50µm apart). Cells are plated 
in either/both chambers and connect via extending processes through the 
channels into the adjacent chamber, creating a rudimentary neural circuit. (D) 
Same as C but includes a third chamber in the centre, allowing for use of three 
different neural subtypes at once, and four smaller red chambers to supply 
collagen mixed with primary astrocytes to the other chambers, allowing for 
neuronal-glial co-culture as well as ECM study. (E) Similar microdevice design 
to that presented in (C) but having five chambers, resulting in two inputs to a 
central port, also having two output chambers. These are all linked by micro 
channels allowing segregated co-culture with directed axonal communication 
as highlighted in (F).
The basic design of microfluidic models demonstrated in Figure 
1C-CF have become a gold standard for in vitro neural models due 
to their many advantages over other model types: unlimited design 
opportunities allowing for increasingly complex designs over time, 
very specific localisation of cells and/or chemicals, higher throughput, 
can be scaled up, highly sequential/parallel experimentation, extremely 
small volumes of media/chemicals per experiment (reducing cost), 
micro-channels allow fluidic isolation between compartments 
stopping the spread of treatments between chambers, greater control 
over cell patterning/manipulation, greater control over extracellular 
and cellular microenvironments, visible to conventional microscopes 
when made with optically transparent material (e.g. PDMS) and are 
low-cost disposable devices.103,104
The original design seen in Fig.1C has been widely used for a 
variety of different co-cultures, with recent examples including: 
cortical neurons,105,106 cortical-cortical and cortical-thalamic co-
culture systems,107,108 hippocampal-glial co culture systems,109,110 
cortical neurons co-cultured with genetically modified astrocytes,111 
embryonic forebrain neurons co-cultured with oligodendrocytes,112 
primary CNS neurons co-cultured with oligodendrocytes and 
astrocytes,113 dendrite growth modelling,114 hippocampal axon 
compression injury,115 synapse formation in hippocampal neurons,116 
embryonic neurons117 and P19-derived neurons co-cultured with 
mouse cortical neurons.118
These models allow for simultaneous segregation and connection 
between two or more cultures of neuronal and/or glial cells. However, 
this connection is equal in both directions, and some models require 
unidirectional connectivity to mimic specific neuronal circuitry. 
In these models discrete cellular connectivity in terms of inputs 
and outputs are used to infer not only elongation of neurites, but 
unidirectional control over axonal connectivity.119,120 Whilst grooves 
and channels orient process growth, it is a linear orientation with no 
directional selectivity, the neuronal processes grow from one chamber 
to the adjacent chamber and vice versa.114 In order to direct neural 
process growth in a single direction only, it is necessary to further 
optimise the design of the micro-channels between chambers. While 
Hattori et al.121 developed an asymmetrical scaffold to promote 
unidirectional connectivity by making the channel ascend as a slope 
in the undesired direction of growth, the selectivity and directional 
pressure was insufficient. An alternative design was later presented by 
Peyrinet al.122 which was similar to the basic microfluidic two-chamber 
device (Figure 1C), but featured asymmetrical micro-channels, aiming 
to create an oriented neural network. This tapered or ‘diode’ micro-
channel design acted as a physical selector of directionality, with 
axons known to respond to physical cues in their microenvironment.
Two characteristics of axons in particular are exploitable for 
device design: axons can act as guide cues for other axons (with 
pioneer axons guiding follower axons through fasciculation and 
axonal bundling) meaning that larger channels accommodate more 
axons as soon as a pioneer axons finds the channel and enters; and 
axons react differently when meeting surfaces at different angles, 
either growing along the surface when aligned in parallel or deviating 
from their original direction when aligned in perpendicular, meaning 
sharp angles can be used to dissuade axonal growth whereas planar 
surfaces support axonal growth.123,124 To this end, Peyrinet al.122 
designed channels that tapered in width from 15μm to 3μm in the 
desired direction of growth. This design imposed unidirectional axon 
connectivity with 97% selectivity.
Micro devices to support the culture of neuronal populations in 
order to mimic those circuits or connected populations found in vivo 
have now been well adopted into the neuroscience community. This 
has, to a large extent, been driven by multidisciplinary working, 
extending the capability of device design and manufacture whilst 
having the application focus of neural engineering. Despite the 
advances made, the majority of these in vitro models have, however, 
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remained largely as 2D cell mono layers. In order to better mimic 
the in vivo tissue environment it is necessary to appreciate the 3D 
structure of the brain and how both neuronal and glial cells interact in 
3D, leading to 3D in vitro neural cell models.
The third dimension
Neuronal and glial cell development in the CNS in vivo relies on 
complex cell-cell interactions in a 3D space.125 By focusing on 2D 
monolayer models, a vital component of in vivo brain structure and 
function is ignored. Hydrogels (such as collagen) are often used 
to present and maintain a 3D cell culture environment, with some 
systems further enabling delivery of therapeutics via the hydrogel 
matrix.126 By designing neural microdevices (as described above) that 
feature imbedded hydrogels to fill the cell culture area, researchers 
are extending the environment from the monolayer presented at the 
lower surface of the chambers into 3D.127–129 As well as the ability to 
interact in 3D space, the use of hydrogels also allows the extracellular 
environment to better mimic the stiffness of the brain, as the in 
vivo brain is soft, having a Young’s modulus of approx. 0.1-16kPa, 
compared to the 20-30GPa of tissue culture plastic or glass. Hydrogels 
are therefore considered to be much more accurate mimics of normal 
CNS tissue compared to the 2D growth surfaces of tissue culture 
plastic or glass,130 with neurons exhibiting faster network formation 
when grown on softer substrates,131,132
Cerebral organoids
An example of the complexity that can be achieved by creating a 
3D in vitro neural model comes in the form of organoid models, in this 
case cerebral organoids. These are supported 3D cell culture models 
which develop spatial regions with discrete identities that influence 
each other, similar to the early stages of the developing brain. Cerebral 
organoids can also exhibit cerebral regions that organise into various 
separated pyramidal identities as well as populations of outer radial 
ganglia,133 or can be fused together to generate a dorsal-ventral axis 
as shown in Figure 2A.134 These organoids represent the developing 
brain and as such have been used as in vitro neural models of 
neurodevelopmental disorders such as microcephaly, where the brain 
size is reduced. Lancaster et al.133 cultured neuroectoderm tissues in a 
spinning bioreactor to rapidly develop brain tissue and form a cerebral 
organoid. After 8-10days neural identity appeared, after 20-30days 
defined brain regions formed, and after two months tissues reached 
maximal size (size limit was hypothesised to be due to the lack of 
a circulatory system and issues with oxygen and nutrient exchange) 
forming complex heterogeneous tissues complete with forebrain, 
midbrain and hindbrain markers and boundaries, as well as tissues 
histologically similar to the cerebral cortex, choroid plexus, retina and 
meninges, that survived for up to 10months in the spinning bioreactor. 
Once the organoid was grown, RNA interference and patient-derived 
iPSCs were used to model microcephaly, which is usually difficult 
to recreate and model in mice or other in vitro models. Whilst these 
organoid models are morphologically and histologically similar to the 
developing brain, they cannot be (or at least have not been to date) 
functionally tested. The main criteria for analysis has focused on 
imaging techniques showing maturation of glial and neuronal cells, as 
well as their spatiotemporal organisation.133
Networked neurospheres
Choi et al.135 used this method to create an in vitro networked 
neurosphere model for Alzheimer’s disease. Neurospheres provide 
the means to present a semi-3D environment on a cluster of cells, 
with individual bodies sometimes referred to as ‘mini-brains’ when 
presenting differentiated neural populations. Choi et al. seeded 
concave micro wells with neural progenitor cells which self-
aggregated to form uniform-sized neurospheres. These matured 
to connect to neighbouring neurospheres forming a multi-neural 
network by day 13. This model was shown to mimic the six organised 
horizontal layers of the cerebral cortex and was used to study the 
neurotoxicity of the protein amyloid beta (Aβ), known to play a part 
in causing Alzheimer’s disease. Adding Aβ tot eh network resulted in 
decreased cell viability and neurite degeneration.135
Figure 2 (A) Embryoid bodies patterned into a singular organoid containing 
ventral (green) and dorsal (red) compartments in a 3D Matrigel structure, 
fusing over time to form a single structure.134 (B) i) Schematic illustration of 
the formation of a neural network within hemicylindrical channel networks, 
shown from the top in ii) with neurite connectivity highlighted by blue 
arrowheads.136 Copyright Permissions obtained from Nature Publishing 
group 2017134 and BioMed central 2015.136
A similar neurospehere network produced by Jeong et al.136 to 
study signal transmission through the CNSas a result of the partial 
breakdown in this system seen in Alzheimer’s disease. Shallow 
(70µm) and deep (300µm) hemicylindrical channel networks 
between concave wells seeded with neural progenitor cells formed a 
self-aggregating network, Figure 2B. During this formation the cells 
differentiated into neuronal and glia cells that secreted laminin and 
formed an extracellular matrix (ECM) around the spheroids. Axonal 
signalling was recorded being transmitted between the spheroids, 
detected by Ca2+ flux imaging.136 Further models are summarised and 
reviewed in.137,138
An important consideration when designing an in vitro model 
of the brain is interstitial fluid flow. In vitro, the main roles of 
interstitial fluid are carried out by the cell culture medium, namely 
providing the cells with nutrients and removing waste during media 
changes. However, this culture medium in vitro is static, while in 
vivo the interstitial fluid flows throughout the brain, and this flow 
has numerous mechanical effects on the cells, as well as affecting 
communication between non-synaptic neurons.139 Reproducing the 
effects of this flow on cells in vitro will help models further mimic 
the in vivo environment, but interstitial fluid flow in the brain is very 
slow, measured at approximately 0.1-0.3 µL min-1,139 and reproducing/
maintaining a flow of this speed can be a complicated process. Park 
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et al. developed an osmosis-driven low-speed laminar flow technique 
to match this slow flow in vitro, allowing for testing of physiological 
flow on neuronal cells in vitro without exposing the cells to shear 
stress found with higher rates of flow.140 The inclusion of flow further 
increases the complexity of the in vitro model. The flow device was 
tested on a 2D culture of primary neural progenitor cells, which 
resulted in an increase in neurite length during differentiation when 
cultured with continuous flow compared to normal culture.141
By combining this osmotic pump with a networked neurosphere 
array, Park et al.142 created an in vitro model they termed a ‘brain-on-
a-chip’ device. This model served not only as a mimic of the brain, 
but as a study of Alzheimer’s disease due to the addition of synthetic 
Aβ protein. Neurospheres were cultured both statically and in a 
dynamic model subjected to 0.15µL min-1 flow rate, with and without 
synthetic Aβ protein. Primary neural progenitor cells were seeded 
and cultured for 10 days to allow neurosphere formation, with toxic 
levels of Aβ protein added from day 7-10, allowing neurospheres 
to form in an environment more akin to Alzheimer’s disease. From 
days 4-10 the static neurospheres did not significantly change in size 
while the neurospheres in the dynamic flow environment increased in 
size. This suggests that flow may accelerate differentiation of neural 
progenitor cells (supported by higher levels of the neuronal marker 
β-III tubulin in the flow model), resulting in neurite outgrowth and 
synaptogenesis, increasing the neurosphere size. In addition, the 
treatment with Aβ had a much greater effect in the dynamic models, 
significantly reducing neurosphere viability and greater disruption 
of the neural networks compared to the static model.142 As with the 
previous 3D culture model employing neurospheres there was limited 
ability to test whether the neurons produced by this method were 
functional; only the differentiation status and morphology of the cells 
was analysed. This model represents a powerful platform for in vitro 
study of neurodegenerative disease, but without functionality testing 
via electrophysiology or other techniques, the resultant neurospheres 
network can only be so useful.
Concluding remarks
As fabrication and micro-manufacturing technology continues to 
improve, these permit more complex device designs to be realised in 
which to house and guide neural tissue engineering. The intricacy of 
these tissues is moving towards that of the central nervous system, 
albeit very slowly, with the enormity of the challenge highlighted by 
the plethora of cell types, their specific connectivity and regionality, 
and the 3D extracellular environment all playing pivotal roles. While 
in vivo models such as animal models have been a hallmark for 
attaining neural complexity in order to simulate a human brain and its 
accompanying disorders, these models may not necessarily the best 
option at present. Indeed, the prevalent nature of neurological disease 
is matched only by the persistent improvements in in vitro model 
technologies, moving from neuronal-only cultures, to neuronal/glial 
mixed cultures, to organised neural networks and circuits within 
microfluidic devices, to bio-artificial organs and organoids, modelling 
the CNS more accurately and efficiently with each leap in complexity.
Neurological disorders and diseases are debilitating conditions 
that currently have no cure. Difficulties of understanding the function 
an organ as complex as the brain, as well as the progression of disease 
and dysfunction contribute to our current stage of advancement in CNS 
research. These difficulties can be mostly abated by studying the brain 
in vitro at a pre-clinical level, but current pre-clinical assessment is 
insufficient to predict which treatments will work on human patients. 
One solution is to develop more efficient in vitro models presenting 
a high level of control and allowing the complexity to be increased 
to make the model more relevant. These models are low-cost and 
reproducible, combining cells with biomaterials and microfluidics to 
make lab-on-a-chip devices, which are the efficient in vitro models 
necessary for progress in research at a pre-clinical level, with the 
resulting data driving clinical trials in a more relevant direction, 
and contributing towards potential treatments for neurological or 
neurodegenerative diseases.
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